Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder.
Adolescent
Attention Deficit Disorder with Hyperactivity
/ drug therapy
Burns
/ epidemiology
Central Nervous System Stimulants
/ therapeutic use
Child
Child, Preschool
Female
Humans
Incidence
Male
Methylphenidate
/ adverse effects
Outcome Assessment, Health Care
Proportional Hazards Models
Retrospective Studies
Risk
Taiwan
/ epidemiology
Attention-deficit/hyperactivity disorder
burn injury
methylphenidate
Journal
Epidemiology and psychiatric sciences
ISSN: 2045-7979
Titre abrégé: Epidemiol Psychiatr Sci
Pays: England
ID NLM: 101561091
Informations de publication
Date de publication:
20 Jul 2020
20 Jul 2020
Historique:
entrez:
21
7
2020
pubmed:
21
7
2020
medline:
26
9
2020
Statut:
epublish
Résumé
Attention-deficit/hyperactivity disorder (ADHD) is associated with a higher risk of burn injury than in the normal population. Nevertheless, the influence of methylphenidate (MPH) on the risk of burn injury remains unclear. This retrospective cohort study analysed the effect of MPH on the risk of burn injury in children with ADHD. Data were from Taiwan's National Health Insurance Research Database (NHIRD). The sample comprised individuals younger than 18 years with a diagnosis of ADHD (n = 90 634) in Taiwan's NHIRD between January 1996 and December 2013. We examined the cumulative effect of MPH on burn injury risk using Cox proportional hazards models. We conducted a sensitivity analysis for immortal time bias using a time-dependent Cox model and within-patient comparisons using the self-controlled case series model. Children with ADHD taking MPH had a reduced risk of burn injury, with a cumulative duration of treatment dose-related effect, compared with those not taking MPH. Compared with children with ADHD not taking MPH, the adjusted hazard ratio for burn injury was 0.70 in children taking MPH for <90 days (95% confidence interval (CI) 0.64-0.77) and 0.43 in children taking MPH for ≥90 days (95% CI 0.40-0.47), with a 50.8% preventable fraction. The negative association of MPH was replicated in age-stratified analysis using time-dependent Cox regression and self-controlled case series models. This study showed that MPH treatment was associated with a lower risk of burn injury in a cumulative duration of treatment dose-related effect manner.
Identifiants
pubmed: 32686635
doi: 10.1017/S2045796020000608
pii: S2045796020000608
pmc: PMC7372158
doi:
Substances chimiques
Central Nervous System Stimulants
0
Methylphenidate
207ZZ9QZ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e146Références
Clin Epidemiol. 2019 May 03;11:349-358
pubmed: 31118821
Pediatrics. 2011 Nov;128(5):1007-22
pubmed: 22003063
Dev Med Child Neurol. 2014 Nov;56(11):1040-1
pubmed: 24920215
JAMA Psychiatry. 2014 Mar;71(3):319-25
pubmed: 24477798
Lancet. 2015 May 30;385(9983):2190-6
pubmed: 25726514
Eur Child Adolesc Psychiatry. 2018 Mar;27(3):279-288
pubmed: 28856464
BMJ. 2014 Jun 18;348:g3769
pubmed: 24942388
BMJ. 2002 Jul 13;325(7355):74
pubmed: 12114236
J Clin Psychiatry. 2018 Jan/Feb;79(1):
pubmed: 29244265
Acta Psychiatr Scand. 1986 Dec;74(6):529-35
pubmed: 3548221
Burns. 2004 Mar;30(2):148-50
pubmed: 15019122
Neuroscience. 2015 Nov 19;309:243-58
pubmed: 25934041
Curr Opin Pediatr. 2007 Oct;19(5):565-9
pubmed: 17885476
JAMA Pediatr. 2015 Apr;169(4):391-5
pubmed: 25686215
Burns. 2014 Nov;40(7):1397-405
pubmed: 24518304
Sleep Med. 2017 Nov;39:95-100
pubmed: 29157595
J Pediatr Psychol. 2004 Mar;29(2):119-30
pubmed: 15096533
Eur Neuropsychopharmacol. 2013 Oct;23(10):1151-64
pubmed: 23165220
J Burn Care Res. 2008 Sep-Oct;29(5):724-9
pubmed: 18695621
Res Dev Disabil. 2018 Jan;72:96-105
pubmed: 29121517
Pediatrics. 2015 Jan;135(1):40-8
pubmed: 25511122
PLoS One. 2017 Mar 15;12(3):e0173762
pubmed: 28296941
Neurosci Biobehav Rev. 2018 Jan;84:63-71
pubmed: 29162520
JAMA Netw Open. 2019 Aug 2;2(8):e198714
pubmed: 31390039
Biol Psychiatry. 2016 Dec 15;80(12):916-922
pubmed: 27086545
Aust N Z J Psychiatry. 1997 Jun;31(3):382-90
pubmed: 9226084
Inj Prev. 2013 Jun;19(3):164-70
pubmed: 23143347
Atten Defic Hyperact Disord. 2015 Mar;7(1):75-87
pubmed: 25148781
Lancet Psychiatry. 2015 Aug;2(8):702-709
pubmed: 26249301
Burns. 2004 May;30(3):221-3
pubmed: 15082347
Eur Child Adolesc Psychiatry. 2010 Apr;19(4):325-40
pubmed: 19823900
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
Biol Psychiatry. 2019 Sep 1;86(5):335-343
pubmed: 31155139
J Affect Disord. 2016 Jan 1;189:110-7
pubmed: 26433758
Burns. 2008 Jun;34(4):546-8
pubmed: 17959315
Pediatrics. 2015 Apr;135(4):e994-1001
pubmed: 25733754
Eur Neuropsychopharmacol. 2014 Dec;24(12):1873-84
pubmed: 25453480
Atten Defic Hyperact Disord. 2014 Dec;6(4):291-302
pubmed: 24705867